The Digital Medicine Society (DiMe) launched an initiative aimed at building an operational, regulatory and evidence framework to scale direct-to-patient (DTP) care pathways. The effort, titled “Optimizing Direct-to-Patient (DTP) Strategies for Pharma,” focuses on access, affordability and patient trust. DiMe said the program will bring together healthcare ecosystem partners, including digital health and pharma stakeholders, to establish “responsible scaling” practices for DTP models. The initiative is framed in part by pressure on drug prices and by growing use of cash-pay distribution channels for high-demand therapies. While DTP expansion remains highly sensitive to compliance and evidence standards, this launch suggests industry coordination is intensifying around how patient-facing models should work across regulated systems—especially for high-cost medicines.